Savitt, Daniel
Jankovic, Joseph
Article History
First Online: 13 April 2019
Compliance with Ethical Standards
:
: No funding was received for the publication of this review
: Dr. Daniel Savitt declares that there are no conflicts of interest relevant to this work. Dr. Joseph Jankovic declares the following: <i>research/training funding</i>—Allergan, Inc., CHDI Foundation, Civitas/Acorda Therapeutics, Dystonia Coalition, Dystonia Medical Research Foundation, F. Hoffmann-La Roche Ltd, Huntington Study Group, Medtronic Neuromodulation, Merz Pharmaceuticals, Michael J. Fox Foundation for Parkinson Research, National Institutes of Health, Neurocrine Biosciences, Parkinson’s Foundation, Nuvelution, Parkinson Study Group, Pfizer Inc., Prothena Biosciences Inc., Psyadon Pharmaceuticals, Inc., Revance Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, and US WorldMeds; <i>consultant/advisory board</i>—Allergan, Inc., Merz Pharmaceuticals, Prothena Biosciences Inc., Retrophin, Inc.–Parexel, Revance Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd; <i>royalties</i>—Cambridge, Elsevier, Future Science Group, Hodder Arnold, Medlink: Neurology, Lippincott Williams and Wilkins, and Wiley-Blackwell.